3D-Bioprinting for cancer biology and precision medicine applications

Back to search results
Cancer patients often respond to therapy, however, many relapse and die from their disease. Identifying the most effective therapy within a clinically relevant time frame is critically important to spare patients from non-effective treatments and improve survival. Tumour organoids have emerged as promising models to study cancer biology and precision medicine. This project aims to develop organoids from patient-derived tumours utilising cutting edge 3D bioprinting technology we recently developed at UNSW. Extensive genetic, biological, and pathological investigation, combined with therapeutic discovery, will advance understanding of cancer biology and precision cancer treatment, ultimately improving cancer care and survival.

The ideal candidate will have some training in biology with an understanding of chemistry. They will be adaptable to working in a multidisciplinary environment of biologists, chemists and engineers. They will have evidence of working in a team environment either in the sciences or volunteer work, while having the ability to also work independently. The candidate will demonstrate a commitment to translating their research outcomes for clinical application. The primary supervisor, Prof Kavallaris, has close links with clinical oncologists and the candidate will work closely with them to train and learn how to design preclinical studies for downstream clinical applications.

Supervisory team
Maria
Kavallaris

Medicine
Children's Cancer Institute and Australian Centre for NanoMedicine
Justin
Gooding

Science
Chemistry
Lakmali
Atapattu

Medicine
Children's Cancer Institute and Australian Centre for NanoMedicine
Register to Apply
Non-UNSW staff/students must Register to Apply
m.kavallaris@unsw.edu.au